7 Years of Hard Work Paid Off - BYHEALTH Develops a Native Strain for the Chinese Population
A new member just joined China’s native probiotics cohort. By-Health Institute of Nutrition & Health (BINH), together with West China School of Public Health (WCSPH) of Sichuan University and Life-Space Global Microecology Research Center, spent 7 years developing Lactobacillus paracasei LPB27.
LPB27 is a high-quality strain discovered from the intestines of healthy Chinese infants. Its potential benefits in boosting immunity and beneficial intestinal bacteria have attracted attention from home and abroad. Industry experts believe that the ongoing breakthroughs in the R&D of high-quality native strains in China will bring more health options to Chinese people, and will also help the long-term development of China's probiotics industry.
Dr. Zhang Xuguang, Executive Director of BINH, researcher of Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences, and visiting professor of Shenzhen University, shared the technical achievement of Lactobacillus paracasei LPB27 for the first time.The R&D results of this strain have been published in many well-known publications such as Bioscience, Biotechnology, and Biochemistry, and Journal of Functional Foods, and received two national patents*, and its application has started. Many internal and external functional evaluation results show that LPB27 has excellent properties, such as gastric acid and bile salt resistance, easy colonization in the intestines, and many benefits, such as anti-inflammation, relief of IgE-mediated allergies, and increasing the number of intestinal beneficial bacteria. It’s on a par with many internationally popular strains in terms of boosting immunity. It’s worth noting that LPB27 is an authentic native Chinese strain. China’s probiotics industry started late, and the core technology of this industry still relies heavily on some leading foreign companies. Over 85% of the strains used in probiotic products on the market come from abroad. Strain R&D has a high technical barrier and requires intensive investments in technology, time and resources. China’s probiotics industry, therefore, has long faced the problem of lacking core technology.
Following the strategy of Science-based Nutrition, By-Health will continue to invest in technology and talents, strengthen its development of probiotic ingredients, promote the application and commercialization of China’s native strains, and help the development of nutrition and health industry.